Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?

Oncol Ther. 2024 Mar;12(1):19-29. doi: 10.1007/s40487-023-00250-7. Epub 2023 Nov 21.

Elisa Agostinetto^#¹, Luca Arecco^#^{1

2}, Evandro de Azambuja³

¹ Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Rue Meylemeersch, 90 (Rez Haut Nord), Anderlecht, 1070, Brussels, Belgium.
² Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132, Genova, Italy.
³ Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Rue Meylemeersch, 90 (Rez Haut Nord), Anderlecht, 1070, Brussels, Belgium. evandro.deazambuja@hubruxelles.be.

^# Contributed equally.

No abstract available

Keywords: Abemaciclib; Adjuvant CDK4/6 inhibitors; Breast cancer; Endocrine therapy; Palbociclib; Ribociclib.